MAZE · Maze Therapeutics, Inc. · Metrics
$32.69
+2.99 (+10.07%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$1.65B
Shares
55.55M
Volume · Oct 20
1.57M
Avg daily vol (3M)
623.78K
MAZE metrics
66 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$32.45
Market cap
$1.65B
Price action
20 metricsPrice change (1W)
+7.2%
Price change (30D)
+32.6%
Price change (3M)
+4.7%
Price change (6M)
+10.7%
Price change (YTD)
-28.3%
Price change (1Y)
+6.8%
Trailing year
Price change (5Y)
—
52-week high
$51.84
52-week low
$22.39
Change from 52-week high
-42.7%
Change from 52-week low
+32.6%
Annualized volatility
67.2%
Annualized volatility (3M)
68.8%
Beta
0.7
RSI (14D)
64.8
Price vs SMA 50
+10.7%
Price vs SMA 200
-7.8%
Avg volume (3M)
605,886
Relative volume
2.1
Average dollar volume
$16.33M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
55.55M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
611.7×
reciprocal yield 0.2%
P / book
3.4
reciprocal yield 29.6%
FCF yield
-7.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-03-25
Profitability
9 metricsGross margin
—
Operating margin
34.4%
Trailing 12 months
Net margin
31.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$145.61M
Net income (TTM)
−$133.59M
Trailing 12 months
Diluted EPS (TTM)
$-2.34
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
-351.0%
Revenue (TTM)
$2.50M
Trailing 12 months
EPS growth YoY
-344.0%
Shares change YoY
+34.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-29.5%
Return on assets
-25.1%
Debt / equity
0.1
Current ratio
18.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$106.84M
Quick ratio
18.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$372.13M
Latest balance sheet
Cash & equivalents
$202.64M
Total assets
$531.62M
Total debt
$38.96M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$106.54M
Capital expenditures (TTM)
$302,000
R&D (TTM)
$121.85M
SG&A (TTM)
—
Stock compensation (TTM)
$26.23M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
162
13F filer change QoQ
-7
Institutional ownership
105.6%
Conviction holders (share of 13F filers)
5.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+12.1%
Holder tenure
4.7
Price vs estimated holder cost
+45.5%
Ownership (registered funds)
1 metricsIndex-fund ownership
9.3%
Short interest
3 metricsShort interest
11.8%
Latest settlement · 6.1 days to cover
Days to cover
6.1d
Short-squeeze score
94 / 100
Insider activity
2 metricsNet insider buying (90D)
−$6.07M
Insider-sentiment score
19 / 100
Risk flags
1 metricsGoing concern
—